Kamunting Street Capital Management’s ProPhase Labs PRPH Stock Holding History

Kamunting Street Capital Management’s Portfolio PRPH Stock Details PRPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9,889	Closed	-$514K	–	62
2021 Q3	$514K	Sell	9,889 -2,430	-20%	-$145K	0.23%	44
2021 Q2	$764K	Buy	12,319 +2,540	+26%	+$143K	0.31%	56
2021 Q1	$723K	Buy	+9,779	New	+$938K	0.29%	65

Other funds holding PRPH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AWE

Avidian Wealth Enterprises Houston, Texas $3.62B AUM 24.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kamunting Street Capital Management's PRPH Position: Q4 2021 in Review

Kamunting Street Capital Management sold out of ProPhase Labs (PRPH) in Q4 2021, closing a stake of 9,889 shares — an estimated $514K sold.

Kamunting Street Capital Management first reported a position in PRPH in Q1 2021 and held it in 3 quarters. The position peaked at $764K in Q2 2021. 25 funds tracked by Wall St. Rank hold PRPH as of Q4 2021.

Kamunting Street Capital Management reported no remaining ProPhase Labs position as of Q4 2021 after selling out during the quarter.
Kamunting Street Capital Management sold 9,889 ProPhase Labs shares in Q4 2021, an estimated $514K.
Kamunting Street Capital Management first reported a position in ProPhase Labs in Q1 2021 and held it in 3 quarters.
Kamunting Street Capital Management's ProPhase Labs position peaked at $764K in Q2 2021.
25 funds tracked by Wall St. Rank held ProPhase Labs as of Q4 2021.

Based on Kamunting Street Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.